A double-blind trial of 0-05% clobetasol proprionate in the treatment of vitiligo.
0-05% clobetasol proprionate (CP) in its proprietary cream base was significantly superior to the cream base alone in the treatment of vitiligo. Twelve of twenty-three patients partially repigmented during 4 months' treatment with CP. All patients showed dermal atrophy with the CP.
D001623:Betamethasone / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D002990:Clobetasol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D012880:Skin Pigmentation / Q000187:drug effects; D014820:Vitiligo / Q000188:drug therapy*
D001623:Betamethasone; D002990:Clobetasol